Biotech

All Articles

AstraZeneca spends CSPC $100M for preclinical heart problem medicine

.AstraZeneca has settled CSPC Drug Group $one hundred million for a preclinical cardiovascular disea...

Zephyrm looks for Hong Kong IPO to cash phase 3 cell treatment trials

.Zephyrm Bioscience is actually gusting toward the Hong Kong stock exchange, filing (PDF) for an IPO...

Frazier Lifestyle Sciences gets $630M for little, mid-cap biotechs

.Frazier Lifespan Sciences has sourced a better $630 million for its fund paid attention to tiny and...

GigaGen amasses up to $135M BARDA money to beat botox

.Antibody aficionado GigaGen, a subsidiary of Spanish biopharma Grifols, is actually increase its ow...

GPCR agency Septerna files for IPO on strength of preclinical data

.Septerna will figure out just how a biotech without "any type of purposeful professional informatio...

Kurma finalizes first $154M haul for greatest biotech fund as yet

.European VC organization Kurma Allies has unveiled its own newest biotech fund, with 140 million eu...

Prothena ensures one director while another leaves behind-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of considerable management hirings, shootings a...

Editas exploit Vertex Cas9 licensing liberties for $57M

.Versus the background of a Cas9 license fight that refuses to perish, Editas Medicine is actually m...

Ultragenyx changes gene treatment dosing to dial up efficacy

.A minority of individuals taking Ultragenyx Pharmaceutical's Wilson condition gene therapy UX701 ha...

Biopharma cutback rate stabilizes in Q3: Strong Biotech analysis

.As summer months heat counts on cool winds, really hopes that this year would bring common field co...